Assessment of the Differences in Pharmacokinetics and Pharmacodynamics Between Four Distinct Formulations of Triamcinolone Acetonide

Zacharias, Leandro Cabral; Lin, Ton; Migon, R.; Ghosn, Corine; Orilla, W.; Feldmann, Barbara; Ruíz, Guadalupe; Li, Yong; Burke, James R.; Kuppermann, Baruch D.

doi:10.1097/iae.0b013e3182647f69

Cited by 38 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 Previous studies found that the physical properties of Triesence were different from those of Trivaris, which leads to different intraocular pharmacokinetics. 21,22 This may imply a different effectiveness and safety profile for treatment of macular edema from both drugs. There have been no published clinical data on the safety and efficacy of intravitreal Triesence in the treatment of macular edema in a clinical setting.…”

Section: Introductionmentioning

confidence: 96%

Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema

Chang

Li²,

Broadhead

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 96%

Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema

Chang

Li²,

Broadhead

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…This has led to the development of preservative-free triamcinolone preparations including Triescence (Alcon, USA) and Trivaris (Allergan, USA). However, these preparations have different pharmacokinetic properties resulting in a shorter duration of action than Kenacort 40 [Zacharias et al 2013].…”

Section: Triamcinolonementioning

confidence: 99%

Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema

Mehta

Gillies

Fraser‐Bell

2015

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Diabetic macular oedema (DMO) is the most common cause of visual loss in the working age population. Intravitreal therapy has superseded macular laser as the firstline treatment for the management of centre-involving DMO in most patients. As well as the proven efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, phase II and III clinical trials of Ozurdex intravitreal dexamethasone implants for DMO have also demonstrated a mean increase in visual acuity and corresponding mean reduction in central macular thickness, particularly in pseudophakic eyes. Because of the risk of visual loss from cataract, glaucoma and intraocular infection with the use of intravitreal steroids, Ozurdex tends to be reserved for use in patients unresponsive to anti-VEGF therapy for centre-involving DMO. Situations where Ozurdex may be considered a first-line treatment option for eyes with centre-involving DMO include pseudophakia, impending cataract surgery, or in the context of a recent arterial thromboembolic event. Because of their stable pharmacokinetics, Ozurdex slow-release implants may also be considered in vitrectomized eyes.

show abstract

“…There appears to be a significant difference in the pharmacokinetics and pharmacodynamics between different triamcinolone acetonide preparations with increased particle size correlating with increased durability and efficacy [67]. A new, simple technique of using centrifugeconcentrated IVTA (Triesence) found triamcinolone to be present in the vitreous for a median of 3 months longer compared to non-concentrated IVTA [68].…”

Section: Triamcinolone Acetonidementioning

confidence: 99%

Corticosteroids for the Treatment of Diabetic Macular Edema

Sharma

Mruthyunjaya

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Diabetic macular edema (DME) is a leading cause of vision loss throughout the world. Three different corticosteroids have been used in the treatment of diabetic macular edema: triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. Intravitreal injection of all three corticosteroids is associated with a similar side effect profile including worsening/formation of cataract, elevation of intraocular pressure, pseudo-endophthalmitis, and infectious endophthalmitis. Sustained-release implants of corticosteroids have recently been studied, and one has recently received FDA approval as the first corticosteroid for the treatment of diabetic macular edema. This review will address some of the major studies evaluating corticosteroids for DME and will focus on studies published within the last 2 years.

show abstract

Assessment of the Differences in Pharmacokinetics and Pharmacodynamics Between Four Distinct Formulations of Triamcinolone Acetonide

Abstract: Triamcinolone acetonide formulations do not have the same pharmacokinetics/pharmacodynamics. Kenalog has the longest vitreous visibility and durability. Particle size appears to correlate with efficacy and durability.

Cited by 38 publications

References 39 publications

Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema

Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema

Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema

Corticosteroids for the Treatment of Diabetic Macular Edema

Contact Info

Product

Resources

About